{"changed_paths":["/protocolSection/statusModule/statusVerifiedDate","/protocolSection/statusModule/lastUpdateSubmitDate","/protocolSection/statusModule/lastUpdatePostDateStruct/date","/protocolSection/outcomesModule/primaryOutcomes/1/description","/resultsSection/outcomeMeasuresModule/outcomeMeasures/1/description"],"citation_text":"TrialDiff Evidence Record evt_NCT02229084_v17_v18_81287f91f229. ClinicalTrials.gov NCT02229084, versions 17-18. Evidence version 1.","claims_not_supported":["That the amendment was scientifically unjustified.","That the change constitutes misconduct or wrongdoing.","That sponsor intent can be inferred from this registry change.","That the change caused or altered the trial's results.","That the change was or was not disclosed in a manuscript.","That TrialDiff determines regulatory compliance or non-compliance.","That co-occurrence with results posting proves the outcome edit was harmless, administrative, or substantively benign.","That event-class membership is a validated global review-priority ranking."],"claims_supported":["TrialDiff compared ClinicalTrials.gov record version 17 to version 18 for NCT02229084.","The JSON Patch for this comparison has hash 304cb43ec0019e315fae4575c9ab0ff7e19a6244e3146db655a1cb519e1add28.","The active deterministic rule set hash was 318445b9ad266f51fd10ef378645c753ba7a098e3e4395c3c457750dc5f88d86.","The deterministic triage label was low; before timing adjustment it was low.","The triage label is uncalibrated metadata, not a validated review-priority finding.","The patch satisfied these deterministic event-class predicates: outcome_edit_cooccurs_with_results_posting.","The timing context for the from-version record was post_recruitment.","The changed JSON Pointer paths were: /protocolSection/statusModule/statusVerifiedDate, /protocolSection/statusModule/lastUpdateSubmitDate, /protocolSection/statusModule/lastUpdatePostDateStruct/date, /protocolSection/outcomesModule/primaryOutcomes/1/description, /resultsSection/outcomeMeasuresModule/outcomeMeasures/1/description.","An outcome path changed between versions 17 and 18 in a patch that also carried a hasResults or resultsSection co-occurrence signal."],"classification":{"calibration_status":"uncalibrated","categories":["results_reconciliation"],"category":"results_reconciliation","deterministic_rules":[],"event_class_rule_set_hash":"07957f8b90549d4f42387f51b471ecde9901b6db63bbc27b84c73631603407c0","event_classes":["outcome_edit_cooccurs_with_results_posting"],"rule_set_hash":"318445b9ad266f51fd10ef378645c753ba7a098e3e4395c3c457750dc5f88d86","severity":"low","severity_pre_timing":"low","timing_context":"post_recruitment","triage_label":"low","triage_rule_set_hash":"af5e5835e00a5fcfe2a17fd02b5fc244c2564104f93f78a1d77d7889f12a178b","value_signals":[{"category":"results_reconciliation","paths":["/protocolSection/outcomesModule/primaryOutcomes/1/description"],"severity":"low","signal":"results_reconciliation_outcome_suppression"}]},"event_id":"evt_NCT02229084_v17_v18_81287f91f229","evidence_version":1,"patch":[{"op":"replace","path":"/protocolSection/statusModule/statusVerifiedDate","value":"2024-05"},{"op":"replace","path":"/protocolSection/statusModule/lastUpdateSubmitDate","value":"2024-05-28"},{"op":"replace","path":"/protocolSection/statusModule/lastUpdatePostDateStruct/date","value":"2024-06-10"},{"op":"replace","path":"/protocolSection/outcomesModule/primaryOutcomes/1/description","value":"The patient-level primary outcome for this objective is pathological Complete Response (pCR), which is binary yes/no, and the study-level endpoint for this outcome is the rate of pCR, i.e. the percentage of patients that achieved pCR=yes.\nThe patient is assessed at the time of surgery for whether they achieved pCR=yes.\nThey have to do the surgery in order to obtain the tissue samples on which they do their pCR assessment.\nPathological Complete Response is defined as the absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes following completion of neoadjuvant systemic therapy (i.e., ypT0N0 or ypTisN0 in the AJCC staging system for staging solid tumors in the neoadjuvant setting that was described in a 2014 FDA Guidance for Industry)."},{"op":"replace","path":"/resultsSection/outcomeMeasuresModule/outcomeMeasures/1/description","value":"The patient-level primary outcome for this objective is pathological Complete Response (pCR), which is binary yes/no, and the study-level endpoint for this outcome is the rate of pCR, i.e. the percentage of patients that achieved pCR=yes.\nThe patient is assessed at the time of surgery for whether they achieved pCR=yes.\nThey have to do the surgery in order to obtain the tissue samples on which they do their pCR assessment.\nPathological Complete Response is defined as the absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes following completion of neoadjuvant systemic therapy (i.e., ypT0N0 or ypTisN0 in the AJCC staging system for staging solid tumors in the neoadjuvant setting that was described in a 2014 FDA Guidance for Industry)."}],"provenance":{"from_snapshot_hash":"70909a794eab1a8f5e457b43ba03450ec7bbc39229c1fc454e7e3c3b2a4f1028","materiality_event_hash":"307e17aa5beb52e9c20799dacbc12aa2d4b77290414bb5d5521b27c432de1ce2","patch_hash":"304cb43ec0019e315fae4575c9ab0ff7e19a6244e3146db655a1cb519e1add28","patch_raw_hash":"630bbc07c0649e2d34b339d574f6f9c4fddf8f4f432a8fc03aec9e927c232ef4","patch_source":"ctgov_internal_history","patch_source_url":"https://clinicaltrials.gov/api/int/studies/NCT02229084/history/17?patchToVersion=18","to_snapshot_hash":"144354df08343d5e332771c3b46b2cbc6d437c814094dd387abf78c7be3640af"},"review_question":"What source document explains this registry amendment, and does it change interpretation of the trial record?","schema":"trialdiff.evidence_record","trial":{"clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02229084","nct_id":"NCT02229084"},"versions":{"from_version":17,"submitted_date":"2024-05-28","to_version":18}}